Cidara Therapeutics, Inc. (CDTX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | - | - | - | 302 |
| Reversal due to settlement of indirect tax liabilities | -3,935 | -5,510 | - | - |
| General and administrative | 6,502 | 6,179 | 4,965 | 4,746 |
| Research and development | 24,817 | 24,600 | 12,429 | 6,657 |
| Acquired in-process research and development | - | - | - | 84,883 |
| Total operating expenses | 27,384 | 25,269 | 17,394 | 96,286 |
| Loss from operations | -27,384 | -25,269 | -17,394 | -95,984 |
| Other expense, net | - | 110 | - | - |
| Interest income, net | 1,666 | 1,899 | 1,859 | 1,774 |
| Other income, net | 1,666 | 1,789 | 1,859 | 1,774 |
| Net loss from continuing operations before income tax expense | - | - | -15,535 | -94,210 |
| Net loss from continuing operations | -25,718 | -23,480 | -15,535 | -94,210 |
| Income from discontinued operations (including loss on disposal of discontinued operations of 1,799 during the three and six months ended june 30, 2024), net of income taxes | - | - | -450 | 3,001 |
| Net loss and comprehensive loss | -25,718 | -23,480 | -15,985 | -91,209 |
| Basic net loss per common share (in dollars per share) | -1.65 | -1.66 | -2.45 | -19.99 |
| Diluted net loss per common share (in dollars per share) | -1.65 | -1.66 | -2.45 | -19.99 |
| Shares used to compute basic net loss per common share (in shares) | 15,547,403 | 14,177,743 | 6,530,111 | 4,563,772 |
| Shares used to compute diluted net loss per common share (in shares) | 15,547,403 | 14,177,743 | 6,530,111 | 4,563,772 |